Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC
Source: SeekingAlpha
2025-12-29 16:50:30 ET
More on Verastem
- Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
- Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)
- Verastem Oncology announces management changes
- Verastem Oncology plans public offering of common stock
Read the full article on Seeking Alpha
For further details see:
Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-2.34% G/L:
$6.27 Last:
375,559 Volume:
$6.36 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
